The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 16, 2021
Filed:
Jan. 03, 2019
Applicant:
Eutilex Co., Ltd., Seoul, KR;
Inventors:
Byoung S Kwon, Gwangmyeong-si, KR;
Seoung-Joo Lee, Gwangmyeong-si, KR;
Joong Won Lee, Gwangmyeong-si, KR;
Seunghyun Lee, Gwangmyeong-si, KR;
Assignee:
Eutilex Co., Ltd., Seoul, KR;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); A61K 38/19 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); A61P 35/04 (2006.01); G01N 33/68 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C07K 16/30 (2006.01); A61P 37/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 38/193 (2013.01); A61K 38/208 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); A61P 37/02 (2018.01); C07K 16/2878 (2013.01); G01N 33/505 (2013.01); G01N 33/5011 (2013.01); G01N 33/6866 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2800/52 (2013.01);
Abstract
Provided are IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.